JPSIM Journal of Pakistan Society of Internal Medicine J Pak Soc Intern Med 2709-8729 2710-0804 Pakistan Society of Internal Medicine 10.70302/jpsim.v2i4.2170 jpsim.v2i4.2170 Original Research Diagnostic Accuracy of Magnetic Resonance Spectroscopy in Diagnosing Carcinoma Prostate Aslam Nazia Arooj Sadaf sadafarooj@hotmail.com * Ameer Saima Imdad Maria Mansoor Mahwish Raja Riffat Punjab Institute of Neurosciences, Lahore Lahore General Hospital, Lahore Bolan Medical College,Quetta Holy family hospital, Rawalpindi *Correspondence: Sadaf Arooj (sadafarooj@hotmail.com) 14 12 2021 2021 2 4 316 319 22 08 2021 02 12 2021 Copyright © 2021 The Author(s) 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective

To determine the diagnostic accuracy of magnetic resonance spectroscopy (MRS) in detection of prostate cancer, rendering histopathology as gold standard.

 Methodology

Descriptive, Cross sectional study conducted from January 2016 to June 2017. Total 206 male patients with clinical suspicion of carcinoma prostate were included in study. Magnetic resonance spectroscopy (MRS) was performed in each patient. The findings were correlated with histopathology report to confirm the diagnosis.

 Results

Out of 206 cases, MRS supported the diagnosis of prostate cancer in 120 (58.25%) patients. Histopathology confirmed prostate cancer in 124 (60.19%) cases whereas 82 (39.81%) patients revealed no prostate cancer. Overall sensitivity, specificity and diagnostic accuracy of magnetic resonance spectroscopy (MRS) in diagnosing carcinoma prostate was 87.10%, 85.37% and 86.41% respectively.

 Conclusion

Magnetic resonance spectroscopy has high diagnostic accuracy in diagnosing prostate cancer.

 Keywords Magnetic resonance spectroscopy has high diagnostic accuracy in diagnosing prostate cancer. References Rasool M, Pansota MS, Tabassum SA, Saleem MS. Frequency of carcinoma of prostate in clinically benign prostatic hyperplasia and role of different screening tests. Pak Armed Forces Med J. 2010;62(3):431-4. Roethke M, Anastasiadis AG, Lichy M, Werner M, Wagner P, Kruck S, et al. MRI guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative biopsy. World J Urol. 2012;30(2):213-8. Hambrock T, Somford DM, Hoeks C, Bouwense SA, H uisman H , Yakar D et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol.2010;183(2):520-7 Caivano R, Cirillo P, Balestra A, Lotumolo A, Fortunato G, Macarini L, et al. Prostate cancer in magnetic resonance imaging: diagnostic utilities of spectroscopies sequences. J Med Imaging Radiat Oncol. 2102;56(6):606-16. Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. Br Med J. 2012:344;d7894 Ackerstaff E, Pflug BR, Nelson JB. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001;61(9):3599-603. Testa C, Schiavina R, Lodi R, Salizzoni E, Tonon C, D’Errico A, et al. Accuracy of MRI/MRSI based transrectal ultrasound biopsy in peripheral and transition zones of the prostate gland in patients with prior negative biopsy. NMR Biomed. 2010;23(9):1017-26. Zakian KL, Eberhardt S, Hricak H. Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging – initial results. Radiology. 2003;229(1):241-7. Yuen JS, Thng CCH, Tan PH. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol. 2004;171(4):1482-6 Prando A, Kurhanewicz J, Borges Ap. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology.2005;236(3):903-10 Weinreb JC, Blume JD, Coakley FV et al. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy – results of ACRIN prospective multi - institutional clinicopathologic study. Radiology 2009;251(1):122-33 Hasumi M, Suzuki K, Oya N, Ito K, Kurokawa K, Fukabori Y, Yamanaka H. MR spectroscopy as a reliable diagnostic tool for localization of prostate cancer. Anticancer Res. 2002;22(2B): 1205-8. Bong Hee Park, Hwang G. Jeon, Seol Ho Choo, Byong Chang Jeong, Seong Il Seo, Seong S. Jeon, Han Y. Choi, Hyun Moo Lee. Role of multiparametric 3.0-Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance. BJU Int volume. 2013;113(6):864-70.